Iran is facing severe disruptions in its pharmaceutical sector following statements from the country’s highest health official. Health Minister Mohammad-Reza Zafarghandi recently confirmed a noticeable rise in medicine prices across the country. He cited major global and domestic supply-chain challenges as the primary drivers behind these cost increases.
Importers previously relied on maritime transport to move raw pharmaceutical materials efficiently to domestic processing facilities. However, recent international supply-chain disruptions have forced suppliers to shift to much more expensive air-freight options. This change in transportation has drastically increased operational costs for manufacturers, significantly pushing up prices for consumers.
The nation’s healthcare infrastructure has also suffered extensive structural damage during recent military conflicts across critical regions. Military actions directly targeted 16 major pharmaceutical manufacturing plants and more than 70 public hospitals. These attacks further reduced domestic production capacity while dramatically increasing national demand for imported medical supplies.
To address severe workforce shortages, health administrators are adjusting financial incentives for specialized medical professionals nationwide. The ministry plans substantial fee increases for doctors specializing in anesthesiology, emergency medicine, and pediatrics. Officials have already implemented partial tariff increases to help retain qualified specialists within the public healthcare system.
These ministerial announcements have coincided with growing public anxiety over the availability of essential seasonal vaccines across the provinces. The Iranian Pharmacists Association has expressed serious concerns about shortages of flu vaccines during critical distribution periods. Private pharmacies currently lack clear information about import volumes, supply sources, and exact delivery schedules.
The pharmaceutical crisis highlights broader economic vulnerabilities within Iran’s healthcare system during times of crisis. Rising prices for essential medicines are placing immense financial pressure on vulnerable households that depend on continuous treatment. Industry leaders are urging the government to take swift action to secure affordable transportation options and protect public health standards.
Moving forward, the ministry intends to streamline alternative supply routes to stabilize the cost of essential medicines. Government officials also plan to rebuild damaged manufacturing plants to restore domestic production capacity as quickly as possible. Future healthcare policies will focus on strengthening emergency supply chains and improving the healthcare system’s resilience against ongoing global disruptions.